EI
BIOA

EAM Investors’s BioAge Labs BIOA Stock Holding History

EAM Investors’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,809
Closed -$609K – 389
2026
Q1 		$609K Buy
+34,809
New +$670K 0.07% 250

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

EAM Investors's BIOA Position: Q2 2026 in Review

EAM Investors sold out of BioAge Labs (BIOA) in Q2 2026, closing a stake of 34,809 shares — an estimated $609K sold.

EAM Investors first reported a position in BIOA in Q1 2026 and held it in 1 quarter. The position peaked at $609K in Q1 2026. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • EAM Investors reported no remaining BioAge Labs position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 34,809 BioAge Labs shares in Q2 2026, an estimated $609K.
  • EAM Investors first reported a position in BioAge Labs in Q1 2026 and held it in 1 quarter.
  • EAM Investors's BioAge Labs position peaked at $609K in Q1 2026.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.